Search

Your search keyword '"Tan DSP"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Tan DSP" Remove constraint Author: "Tan DSP"
67 results on '"Tan DSP"'

Search Results

1. Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

3. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

6. The genomic profile of HER2 ‐amplified breast cancers: the influence of ER status

7. ESR1 amplification in endometrial carcinomas: hope or hyperbole?

8. Mechanisms of transcoelomic metastasis in ovarian cancer.

9. Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.

10. Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.

11. Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract.

12. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

13. Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.

14. Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.

15. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.

16. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

17. Targeting the immune microenvironment for ovarian cancer therapy.

18. Erratum: Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium.

20. Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium.

21. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.

23. The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.

24. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.

25. Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.

26. Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials.

27. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.

28. Proportions and incidence of locally advanced cervical cancer: a global systematic literature review.

29. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.

30. Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.

31. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.

33. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.

34. Correction: PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production.

35. Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.

36. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.

37. A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.

38. Editorial: Harnessing DNA Damage Response in Gynecologic Malignancies.

39. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.

40. PLK1 inhibition selectively induces apoptosis in ARID1A deficient cells through uncoupling of oxygen consumption from ATP production.

41. Clear cell carcinoma of the endometrium.

42. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.

43. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.

44. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives.

45. Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives.

46. Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma.

47. GAGE mediates radio resistance in cervical cancers via the regulation of chromatin accessibility.

48. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.

49. The systemic treatment of recurrent ovarian cancer revisited.

50. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

Catalog

Books, media, physical & digital resources